Clinical Case Study of ABO Hemolytic Disease in Full-term Newborns with Positive Free Test and Direct Antiglobulin Test

Yan Jin

2021

Abstract

ABO hemolytic disease of newborn (ABO-HDN) occurs early and progresses rapidly, which can lead to fetal or neonatal anemia and neonatal hyperbilirubinemia. Severe intrauterine hemolysis can lead to fetal edema, which can lead to fetal death or neonatal death. Severe or very severe hyperbilirubinemia can be complicated with bilirubin encephalopathy, Affect the quality of life of newborns.In this study, full-term children with ABO-HDN were divided into two groups according to the results of three serological tests of hemolysis. Group A: single antibody release test (ART) was positive; Group B: ART positive, combined with at least one hemolysis test positive in direct antiglobulin test (DAT) and free antibody test (FAT). The differences of minimum hemoglobin, age at onset (h) and incidence of anemia between group A and group B were compared.

Paper Citation

in Harvard Style

Jin Y. (2021). Clinical Case Study of ABO Hemolytic Disease in Full-term Newborns with Positive Free Test and Direct Antiglobulin Test. In Proceedings of the 2nd Conference on Artificial Intelligence and Healthcare - Volume 1: CAIH, ISBN 978-989-758-594-4, pages 47-51. DOI: 10.5220/0011163000003444

in Bibtex Style

@conference{caih21,
author={Yan Jin},
title={Clinical Case Study of ABO Hemolytic Disease in Full-term Newborns with Positive Free Test and Direct Antiglobulin Test},
booktitle={Proceedings of the 2nd Conference on Artificial Intelligence and Healthcare - Volume 1: CAIH,},
year={2021},
pages={47-51},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0011163000003444},
isbn={978-989-758-594-4},
}

in EndNote Style

TY - CONF

JO - Proceedings of the 2nd Conference on Artificial Intelligence and Healthcare - Volume 1: CAIH,
TI - Clinical Case Study of ABO Hemolytic Disease in Full-term Newborns with Positive Free Test and Direct Antiglobulin Test
SN - 978-989-758-594-4
AU - Jin Y.
PY - 2021
SP - 47
EP - 51
DO - 10.5220/0011163000003444